Today, January 24, INESSS issued a notice titled Anti-Angiogenic Drugs in the Treatment of Age-Related Macular Degeneration: Issues Associated with their Use in Québec.  

This notice was produced at the request of the Minister of Health and Social Services and aims to shed light on the issues raised by the use of two anti-angiogenic agents, ranibizumab (Lucentis^TM) and bevacizumab (Avastin^TM), for the treatment of age-related macular degeneration (AMD). It is intended for all decision makers involved, including patients, physicians, pharmacists and administrators. This notice is not part of the evaluation process for registration on the lists of medications covered by the public plan. 

We invite you to consult the notice summary to learn more about the main results and to download the complete report (in French). 

You may also access the press release (in French) on this topic.